Comparison between Avience Biomedicals IPO and Galaxy Medicare IPO.
Avience Biomedicals IPO is a SME Bookbuilding IPO proposed to list at NSE SME while Galaxy Medicare IPO is a SME Bookbuilding proposed to list at NSE SME.
| Avience Biomedicals IPO | Galaxy Medicare IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | NSE SME | NSE SME |
| Lead Managers | Fintellectual Corporate Advisors Pvt.Ltd. | Affinity Global Capital Market Pvt.Ltd. |
| Registrar | Skyline Financial Services Pvt.Ltd. | Cameo Corporate Services Ltd. |
| Market Maker | Asnani Stock Broker Pvt.Ltd. | Prabhat Financial Services Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | |
| Final Prospectus | Final Prospectus | |
| Anchor Investor | ||
| IPO Allotment URL | IPO Allotment URL |
The total issue size of Avience Biomedicals IPO is up to ₹0.00 Cr whereas the issue size of the Galaxy Medicare IPO is up to ₹21.19 Cr. The final issue price of Avience Biomedicals IPO is and of Galaxy Medicare IPO is ₹54.00 per share.
| Avience Biomedicals IPO | Galaxy Medicare IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹51.00 per share | |
| Issue Price (Upper) | ₹54.00 per share | |
| Issue Price (Final) | ₹54.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 2000 shares | |
| Fresh Issue Size | 15,27,600 shares | 31,00,000 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹16.74 Cr |
| OFS Issue Size | 0 shares | 8,24,000 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹4.45 Cr |
| Issue Size Total | 15,27,600 shares | 39,24,000 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹21.19 Cr |
Avience Biomedicals IPO opens on , while Galaxy Medicare IPO opens on Sep 10, 2025. The closing date of Avience Biomedicals IPO and Galaxy Medicare IPO is , and Sep 12, 2025, respectively.
| Avience Biomedicals IPO | Galaxy Medicare IPO | |
|---|---|---|
| Anchor Bid Date | ||
| Issue Open | Sep 10, 2025 | |
| Issue Close | Sep 12, 2025 | |
| Basis Of Allotment (Tentative) | Sep 15, 2025 | |
| Initiation of Refunds (Tentative) | Sep 16, 2025 | |
| Credit of Share (Tentative) | Sep 16, 2025 | |
| Listing date (Tentative) | Sep 17, 2025 | |
| Anchor Lockin End date 1 | ||
| Anchor Lockin End date 2 |
Avience Biomedicals IPO P/E ratio is , as compared to Galaxy Medicare IPO P/E ratio of 19.01.
| Avience Biomedicals IPO | Galaxy Medicare IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)Avience Biomedicals Ltd.'s revenue increased by 89% and profit after tax (PAT) rose by 239% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated)Galaxy Medicare Ltd.'s revenue increased by 9% and profit after tax (PAT) dropped by 9% between the financial year ending with March 31, 2025 and March 31, 2024.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 92.85 | 99.57 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 66.37 | 72.43 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 19.01 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹81.93 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 50.14 | 19.88 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 24.84 | 22.38 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.97 | 0.25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹2.84 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 50.14 | 18.35 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Avience Biomedicals IPO Retail Individual Investors (RII) are offered 0 shares while in Galaxy Medicare IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in Avience Biomedicals IPO and 80,000 shares in Galaxy Medicare IPO.
| Avience Biomedicals IPO | Galaxy Medicare IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | |
| Market Maker Reservation | 80,400 shares | 2,08,000 shares |
| QIB | 0 shares | 80,000 shares |
| NII | 0 shares | 15,36,000 shares |
| RII | 0 shares | 23,08,000 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 0 shares | 39,24,000 shares |
Avience Biomedicals IPO subscribed in total, whereas Galaxy Medicare IPO subscribed 1.83x.
| Avience Biomedicals IPO | Galaxy Medicare IPO | |
|---|---|---|
| QIB (times) | 1.00x | |
| NII (times) | 1.48x | |
| Big NII (times) | 1.88x | |
| Small NII (times) | 0.66x | |
| RII (times) | 2.10x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 1.83x |
